Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267


Delayed Quote. Delayed Swiss Exchange - 09/13 11:31:24 am
86.66 CHF   -1.52%
09/14NOVARTIS : Trial and Error -2-
09/14NOVARTIS : Trial and Error
09/14NOVARTIS : The Startup That Manipulated Data to Get a -2-
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : Vows More Transparency

share with twitter share with LinkedIn share with facebook
share via e-mail
09/10/2019 | 02:48am EDT

By Denise Roland

Novartis AG, under fire for keeping a data-manipulation issue under wraps for several months, vowed to more quickly disclose any similar concerns in the future.

Chief Executive Vas Narasimhan told investors at an event in London on Monday that Novartis has committed to notify the Food and Drug Administration within five business days of any "credible allegation" of manipulation of data that had been submitted to the agency for drug approval.

The FDA last month said the Swiss company could face criminal penalties for holding back a data-manipulation concern with Zolgensma during the gene therapy's approval process. Novartis notified the FDA of the concern in late June, a month after the drug was approved, despite the issue being known inside the company since the middle of March.

Dr. Narasimhan has said the company wanted to investigate the specifics of the manipulation before bringing the concern to the agency. He said he was made aware of the issue in early May after an initial investigation found the allegations were credible.

But the timeline of those decisions has raised suspicions from the agency, and some politicians, that Novartis kept the issue under wraps because it didn't want to delay the approval of Zolgensma.

The treatment, which costs in the range of $2.1 million for a one-time infusion, treats children with an especially devastating, sometimes fatal form of spinal muscular atrophy. It is one of the first in a wave of gene therapies that promise to cure certain intractable diseases with one dose. They work by supplying a functioning version of the gene at fault.

The FDA gave Novartis the green light to sell Zolgensma in late May, and the company put it on sale at a price of $2.1 million, making it the world's most expensive drug. Dr. Narasimhan has said the approval timeline for Zolgensma wasn't a factor.

"It's difficult for us to exercise judgment without it being later considered maybe not the best judgment, so we're just taking judgment out of the equation," Dr. Narasimhan said of the five-day pledge at the investor event, which focused on environmental, social and corporate governance.

The FDA has said the data manipulation, which related to mouse studies carried out to compare different batches of Zolgensma, didn't affect its view that the gene therapy is safe and effective.

It referred the matter to its Office for Criminal Investigations.

Submitting false data to the agency as part of a new-drug application could be a crime if investigators prove the actions were intentional and not an oversight.

The episode also has drawn criticism from several high-ranking politicians including Sen. Chuck Grassley (R., Iowa) and Democratic presidential candidates Sens. Elizabeth Warren of Massachusetts and Bernie Sanders of Vermont.

Write to Denise Roland at Denise.Roland@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS
09/14NOVARTIS : Trial and Error -2-
09/14NOVARTIS : Trial and Error
09/14NOVARTIS : The Startup That Manipulated Data to Get a -2-
09/14NOVARTIS : The Startup That Manipulated Data to Get a Miracle Drug to Market
09/13NOVARTIS : New Novartis data show Mayzent can help preserve mobility for longer ..
09/13NOVARTIS : New Novartis data show that neuronal and glial filaments, biomarkers ..
09/12NOVARTIS : New Novartis data show Mayzent® can help preserve mobility for longer..
09/11Swiss Biotech Anokion Raises $40 Million in Series B Round
09/10NOVARTIS : NATIONALLY RANKED ROSEN LAW FIRM Continues To Investigate Securities ..
09/10NOVARTIS : data confirm long-term efficacy and safety of Aimovig for majority of..
More news
Financials (USD)
Sales 2019 46 926 M
EBIT 2019 13 830 M
Net income 2019 10 117 M
Debt 2019 17 463 M
Yield 2019 3,39%
P/E ratio 2019 18,9x
P/E ratio 2020 20,6x
EV / Sales2019 4,64x
EV / Sales2020 4,28x
Capitalization 200 B
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 94,54  $
Last Close Price 87,47  $
Spread / Highest target 22,9%
Spread / Average Target 8,08%
Spread / Lowest Target -6,80%
EPS Revisions
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS18.45%200 777
JOHNSON & JOHNSON1.07%345 150
ROCHE HOLDING LTD.10.52%236 116
PFIZER-15.44%204 151
NOVO NORDISK AS14.89%118 168